Fast Track Designation received for Prader-Willi syndrome treatment
Levo Therapeutics has received Fast Track Designation from the FDA for LV-101 (intranasal carbetocin) for the treatment of Prader-Willi syndrome.
List view / Grid view
Levo Therapeutics has received Fast Track Designation from the FDA for LV-101 (intranasal carbetocin) for the treatment of Prader-Willi syndrome.
26 April 2016 | By Victoria White, Digital Content Producer
Alizé Pharma has announced top-line results of a Phase II clinical trial of AZP-531 in patients with Prader-Willi Syndrome (PWS)...